Physician profile
Nathalie D Mckenzie
NPI 1598966061
$223,434.20
in general payments reported to CMS, 2019-2025
27 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $6,908 · 2021: $2,731 · 2022: $54K · 2023: $68K · 2024: $35K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Consulting Fee: $26K · Travel and Lodging: $15K · Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,310.00 |
| Consulting Fee | $26,197.50 |
| Travel and Lodging | $15,414.43 |
| Food and Beverage | $2,697.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88,843.70 | 2020-2025 | Lynparza, Keytruda |
| Seagen INC. | $47,562.93 | 2021-2023 | Tivdak |
| Clovis Oncology, INC. | $27,087.93 | 2019 | |
| Glaxosmithkline, LLC. | $20,300.24 | 2020-2025 | Jemperli, Zejula |
| Pfizer INC. | $19,180.00 | 2024-2025 | |
| Genmab U.S., INC. | $8,600.41 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $3,543.04 | 2019-2025 | Lynparza |
| Immunogen, INC. | $2,250.00 | 2023 | Elahere |
| Daiichi Sankyo INC. | $1,860.00 | 2024 | |
| Intuitive Surgical, INC. | $810.85 | 2019-2024 | Da Vinci Surgical System |
| F. Hoffmann-La Roche Ag | $600.00 | 2021 | |
| Tesaro, INC. | $471.28 | 2019 | |
| Abbvie INC. | $381.17 | 2024-2025 | |
| Biom'Up France Sas | $321.41 | 2021 | |
| Ethicon US, LLC | $201.89 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $201.21 | 2022-2023 | Precisetumor |
| Integra Lifesciences Corporation | $168.11 | 2020-2023 | Biodrestore, Biodfactor, Biofix |
| Conmed Corporation | $152.34 | 2019 | |
| Momentis Surgical INC. | $136.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Medtronic, INC. | $124.97 | 2022 | |
| Fennec Pharmaceuticals, INC. | $121.85 | 2025 | Pedmark |
| Gilead Sciences, INC. | $107.98 | 2024 | Trodelvy |
| Allergan, INC. | $99.02 | 2021 | |
| Davol INC. | $93.44 | 2023 | Arista Ah Flexitip |
| Applied Medical Resources Corporation | $76.59 | 2020 | |
| Foundation Medicine, INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathalie Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.